Hyperlipidemias
22 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Autoinjector + EVOLOCUMAB for hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for hyperlipoproteinemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Barley beta-glucan(3.0g) for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for homozygous familial hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hyperlipoproteinemia type v | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DR10624 Injection for hypertriglyceridemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Enlicitide for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Chloride for hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Decanoate for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Enlicitide Decanoate for hyperlipoproteinemia type ii | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Evolocumab for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| High-intensity Mediterranean diet intervention for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MAR001 for hypertriglyceridemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olezarsen for hyperlipoproteinemia type i | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SHR-1918 for homozygous familial hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hypercholesterolemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hyperlipoproteinemia type ii | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |